Market Overview

UPDATE: Cantor Fitzgerald Initiates Coverage on Bruker

Share:
Related BRKR
Bruker Introduces MALDI Tissuetyper Solution With New High Speed RapifleX MALDI-TOF MS System For Anatomical Pathology Research
Otonomy, Renren And Other Names To Watch Heading Into Next Week

According to a research report published Thursday, Cantor Fitzgerald has initiated Bruker (NASDAQ: BRKR) with a Buy rating and $16 PT.

In the report, Cantor Fitzgerald said, "Bruker has a highly diversified high-end scientific instrumentation portfolio targeting life science, applied, and industrial markets. In our view, the company is well positioned to capitalize on high-growth market segments over the next several years and deliver above-market top line growth, leveraging internal R&D and strategic tuckins. Additionally, with below sector average margins, Bruker has significant upside for margin expansion in the medium-term."

Bruker closed Wednesday at $13.39.

Latest Ratings for BRKR

DateFirmActionFromTo
May 2015William BlairDowngradesOutperformMarket Perform
May 2015Mizuho SecuritiesDowngradesBuyNeutral
Apr 2015Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Analyst Ratings

 

Related Articles (BRKR)

Around the Web, We're Loving...

Get Benzinga's Newsletters